Atria Investments Inc Raises Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Atria Investments Inc lifted its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 135.4% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 30,856 shares of the company’s stock after acquiring an additional 17,746 shares during the period. Atria Investments Inc’s holdings in Teva Pharmaceutical Industries were worth $556,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Sequoia Financial Advisors LLC boosted its position in Teva Pharmaceutical Industries by 0.7% in the third quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock valued at $2,025,000 after buying an additional 805 shares during the last quarter. Signaturefd LLC boosted its position in Teva Pharmaceutical Industries by 16.9% in the third quarter. Signaturefd LLC now owns 7,583 shares of the company’s stock valued at $137,000 after buying an additional 1,094 shares during the last quarter. QRG Capital Management Inc. boosted its position in Teva Pharmaceutical Industries by 0.8% in the second quarter. QRG Capital Management Inc. now owns 144,938 shares of the company’s stock valued at $2,355,000 after buying an additional 1,191 shares during the last quarter. United Services Automobile Association boosted its position in Teva Pharmaceutical Industries by 3.1% in the second quarter. United Services Automobile Association now owns 41,159 shares of the company’s stock valued at $669,000 after buying an additional 1,249 shares during the last quarter. Finally, GAMMA Investing LLC boosted its position in Teva Pharmaceutical Industries by 105.7% in the second quarter. GAMMA Investing LLC now owns 3,388 shares of the company’s stock valued at $55,000 after buying an additional 1,741 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Up 1.9 %

Shares of TEVA stock opened at $16.80 on Wednesday. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. The company has a market cap of $19.03 billion, a price-to-earnings ratio of -19.51, a PEG ratio of 1.28 and a beta of 0.87. The stock has a 50 day simple moving average of $17.75 and a 200-day simple moving average of $17.28. Teva Pharmaceutical Industries Limited has a 1-year low of $9.04 and a 1-year high of $19.31.

Analysts Set New Price Targets

TEVA has been the topic of a number of recent research reports. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. JPMorgan Chase & Co. boosted their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. UBS Group boosted their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Finally, Barclays boosted their price target on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $19.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.